Taysha Gene Therapies’ (TSHA) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report released on Monday,Benzinga reports. Cantor Fitzgerald currently has a $7.00 price target on the stock.

Several other research analysts have also recently issued reports on TSHA. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Up 2.3 %

Taysha Gene Therapies stock opened at $1.80 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $4.32. The stock has a market capitalization of $369.10 million, a PE ratio of 2.86 and a beta of 0.96. The business’s fifty day moving average is $1.55 and its 200 day moving average is $1.80.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $2.05 million. On average, sell-side analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in Taysha Gene Therapies by 7.0% during the first quarter. Rhumbline Advisers now owns 205,462 shares of the company’s stock valued at $286,000 after buying an additional 13,383 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Taysha Gene Therapies by 26.4% in the fourth quarter. Wellington Management Group LLP now owns 585,594 shares of the company’s stock worth $1,013,000 after purchasing an additional 122,402 shares during the period. Squarepoint Ops LLC boosted its position in shares of Taysha Gene Therapies by 105.4% in the fourth quarter. Squarepoint Ops LLC now owns 211,842 shares of the company’s stock worth $366,000 after purchasing an additional 108,719 shares during the period. Rafferty Asset Management LLC bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth approximately $436,000. Finally, ProShare Advisors LLC boosted its position in shares of Taysha Gene Therapies by 32.3% in the fourth quarter. ProShare Advisors LLC now owns 59,076 shares of the company’s stock worth $102,000 after purchasing an additional 14,418 shares during the period. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.